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toring was defined as receipt of1 serum ferritin test after 10th unit. ICT-eligibility
was defined as 2 serum ferritin tests 1,000 g/L or 20 units transfused. ICT
treatment was defined as 1 prescription/administration for deferasirox or defer-
oxamine. Kaplan-Meier and Cox proportional hazards regression methods were
used to compare overall survival. RESULTS: A total of 163 patients were included;
58.3% and 30.1% received20 and30 RBC units, respectively. A total of 50.3% had
leukemia and 20.2% had myelodysplastic syndrome as the underlying disease. A
total of 44.8%, 53.7% and 67.3% of patients receiving 10, 20 and 30 RBC units,
respectively, were monitored for TIO. Compared to unmonitored patients, TIO-
monitored patients had significantly longer median OS (16.13 vs. 2.30 months;
log-rank p-value0.001) even after confounder adjustment (hazards ratio 0.271;
p-value0.001). Among 99 ICT-eligible patients, 9% received ICT; 8 (88.9%) received
deferasirox. Median OS for ICT-treated patients and untreated patients was 9.48
and 7.16 months, respectively (log-rank p-value0.593). CONCLUSIONS: To con-
clude, TIO monitoring after 10 RBC units may be associated with survival benefits,
but 50% of patients receiving 10 transfusions were monitored for TIO. Clinical
benefits of chelating cancer patients have not been established and additional
studies are necessary to ascertain the impact of TIO and chelation utility among
cancer patients.
PSY7
A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY
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OBJECTIVES: Acquired hemophilia (AH) is a rare disorder (1 per 1.3 million) char-
acterized by auto-antibodies to factor VIII. AH is characterized by life-threatening
bleeding and high mortality. Recombinant factor VIIa (rFVIIa) received FDA ap-
proval for treatment of AH in 2006. As part of the post-approval commitment, Novo
Nordisk agreed to use a society-owned research registry to monitor treatment of
AH bleeding episodes. This required IRB approval and informed consent. For sites
with few patients and/or limited research staff, the registry was not a feasible
option METHODS: An alternative web-based, IRB-exempt reporting method, Ac-
quired Hemophilia Surveillance (AHS, www.novosevensurveillance.com), was es-
tablished to collect data on rFVIIa use in AH and associated adverse events under
the HIPAA safety surveillance waiver. RESULTS: From April 2008-January 2011, 32
reporters submitted 80 case reports (32 male/48 female). The mean age was 65
years (range 16-97). Common associated conditions were autoimmune disorders
(32 patients), malignancy (6 patients) and post-partum state (5 patients). On aver-
age, 5 discrete bleeding events per patient (range 0-100) were reported; 75 case
reports described bleeding as spontaneous (88%), surgical (16%), and/or related to a
procedure (15%). No bypassing agent was reported to have been used in 17 (21%).
rFVIIa was used in 50 (63%), the majority of which were first-line (39, 78%). AH was
reported to have been “resolved” in 44 (55%), “not resolved” in 19 (24%), and “un-
sure” in 16 (20%); mean(median) time to resolution was 7.2(2) months (range 1-52).
There were no reported deaths. None of the 50 rFVIIa-treated cases suffered an
adverse or thrombotic event (AE). CONCLUSIONS: AHS provides an innovative ap-
proach for hemophilia treatment centers and hematology/oncology practices to
capture basic safety surveillance data for patients with Acquired Hemophilia. The
AHSproject provides additional information aboutAH treatment, and reaffirms the
safety of rFVIIa and the low rate of thrombotic complications.
Systemic Disorders/Conditions – Cost Studies
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OBJECTIVES: Compare costs of privately-insured oxymorphone extended-release
tablet (“oxymorphone”) users with those of oxycodone controlled-release tablet
(“oxycodone”) users, from an employer’s perspective. METHODS: Patients, ages
18, with 1 claim for oxymorphone/oxycodone during Q2:2006-Q4:2009 were
identified in de-identified private payer claims data and observed from the first
such claim (“index date”) until the earliest of: use of comparator drug; end of
continuous eligibility; or 12 months (“study period”). Continuous eligibility was
required throughout a 6-month baseline period and1month after the index date.
Patients with claims for any formulation (extended-release or otherwise) of the
comparator drug during the first 30 days of the study periodwere excluded, aswere
patients pregnant during the baseline/study periods. Study period risk-adjusted
costs were estimated per patient-month using generalized estimating equations
controlling for baseline demographics, resource use, and costs. Medical/drug (di-
rect) costs paid by private insurers were reported for patients ages 18-64 (N 8,354)
and 65 (N  3,515) as well as subsets of each without cancer during the baseline/
study periods (N  7,090 and N  2,444, respectively). Medically-related absentee-
ism and disability (indirect) costs were reported for all employees, ages 18-64, (N
1,313) and employeeswithout cancer (N 1,146). Bias-corrected bootstrappingwas
used to compare third-party payer costs. RESULTS: Oxymorphone users, ages 18-
64, had lower drug costs ($693 vs. $763, p0.0035) and similar medical costs ($1,875
vs. $1,976, p0.3570) per patient-month compared with oxycodone users. Indirect
costs were not different ($662 vs. $670, p0.9370). Oxymorphone users, ages 65,
had similar Medicare supplemental drug costs ($533 vs. $588, p0.0840) and signif-
icantly lower medical costs ($459 vs. $747, p0.0001). Results were comparable for
the subsets without cancer. CONCLUSIONS: After controlling for baseline charac-
teristics, real-world evidence suggests that, from an employer’s perspective, oxy-
morphone users may incur lower monthly direct costs than oxycodone users.
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HEALTH CONSEQUENCES AND COSTS OF TACHOSIL® AS HAEMOSTATIC
TREATMENT IN LIVER SURGERY VERSUS TISSUCOL®: A RETROSPECTIVE
OBSERVATIONAL COHORT STUDY
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OBJECTIVES: The objective of this study was to compare the effectiveness and
costs of TachoSil® carrier-bound collagen sponges versus Tissucol® fibrin glue in
patients undergoing liver surgery in current medical practice.METHODS: A retro-
spective observational cohort study was carried out including 244 patients (128 in
TachoSil® group and 116 in Tissucol® group) that underwent a liver surgery a
university hospital. Data on demographics, medical background, effectiveness, re-
source consumption and complicationswere obtained by reviewing patients=med-
ical records. Unit costs were obtained from financial hospital records and drug
costs from the Spanish health authorities. Collection of patient data took place
from definitive surgery until hospital discharge using a hospital=s perspective.
Variables collected to estimate costs and effectiveness were haemostatic drugs,
surgical time, drainage, blood transfusions and hospitalisation days. Research out-
comes were presented as the differences in effectiveness measures and costs for
the collected variables using statistical analysis (p0.05).RESULTS:WithTachoSil®
significantly less patients required a drainage (12.5% vs. 52.6%, p0.001) and pa-
tients were hospitalized for a minor number of days (median 6 vs. 8 days,
p0.00013). No statistical differences between both groups were observed in the
rest of the effectiveness data pre- and postoperative. The TachoSil® group showed
significant lower mean costs with respect to haemostatic drugs (mean [SD] euro,
974€ [787€] vs. 987€ [384€], p0.03) and drainage (3€ [7€] vs. 12€ [11€], p0.00). No
significant differences in other costs between both treatments were reported.
CONCLUSIONS: TachoSil® showed to reduce drainage and hospitalisation days.
However no significant lower total costs for the TachoSil® group (10,212€ [8,197€])
vs. the Tissucol® group (10,224€ [7,394€]) could be demonstrated.
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COST ANALYSIS OF ANEMIA TREATMENT WITH ERYTHROPOIESES-
STIMULATING AGENTS (ESAS) IN CANCER PATIENTS RECEIVING
CHEMOTHERAPY: A MULTICOUNTRY APPROACH
Duran A1, Spaepen E2, Lamotte M3, Walter E4, Lucioni C5, Pinheiro B6, Brosa M7,
Kutikova L8, Pujol B8, Annemans L9
1IMS Health, London, UK, 2SBD Analytics BVBA/SPRL, Bekkevoort, Belgium, 3IMS Health,
Vilvoorde, Belgium, 4Institute for Pharmacoeconomic Research, Vienna, Austria, 5Wolters Kluwer
Health Italy, Milan, Italy, 6Centro de Investigação Sobre Economia Portuguesa, Lisbon, Portugal,
7Oblikue Consulting, Barcelona, Spain, 8Amgen (Europe) GmbH, Zug, Switzerland, 9I-CHER
Interuniversity Centre for Health Economics Research, Gent, Belgium
OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin alfa (DARB), epoetin alfa (EPO-A) and epoetin beta
(EPO-B) in the treatment of chemotherapy-induced anemia, using propensity score
matching. The study was performed using the IMS Hospital Disease Database, a
longitudinal database unique to Belgium containing individual patient/admission-
level data on diagnoses, procedures, and pharmaceuticals. Given the limited avail-
ability of other databases reporting the same level of information in other Euro-
pean countries, the objectives of this study were to assess the applicability of the
Belgian analysis, and to estimate differences in costs between ESAs in Austria,
Italy, Portugal, and Spain. METHODS: To adapt the analysis, costs were replaced
with country-specific costs and discrepancies in epidemiology and treatment pat-
terns were examined. Adjusting for country discrepancies, costs were analyzed
using a mixed-effects model stratifying for propensity score quintiles as in Spa-
epen 2008. Sources included Eurostat, national cancer registries, IMS sales data,
and reimbursement and treatment guidelines for procedures and drugs. RESULTS:
All populations were comparable to Belgium in terms of age, gender, ESA use, and
blood transfusions. Adjusting for chemotherapy use and tumor-specific cancer
incidence, total costs (Euro, 2010)withDARBwere 22-26% lower compared to EPO-A
and 20-35% lower compared to EPO-B. Anemia-related costs were lowest for DARB
€2,585154, EPO-A €3,10299, EPO-B €2,969166 in Austria; DARB €3,144211,
EPO-A €5,049119, EPO-B €3,656230 in Italy; DARB €2,153117, EPO-A €2,44663,
EPO-B €2,654124 in Portugal; and DARB €2,378143, EPO-A €3,34975, EPO-B
€2,857153 in Spain. CONCLUSIONS: Total and anemia-related costs were lowest
in patients receiving DARB compared to EPO-A or EPO-B in all countries. Although
it was not possible to account for all differences among countries, the findings are
in line with those from the Belgian analysis, and demonstrate the feasibility of
adapting such data to other settings accounting for patient characteristics and
treatment costs.
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OBJECTIVES: In common with other chronic conditions, fibromyalgia syndrome
(FMS) adversely affects Health-Related Quality of Life (HRQoL) and functional sta-
tus. FMS often results in disability and profoundly affects the performance of daily
activities, both at work and at home. This study was conducted to assess the
patient-level burden among subjects with FMS. METHODS: A prospective, obser-
vational studywas carried out on FMSpatients from44medical centers throughout
Korea. HRQoL scores were obtained using the Short Form (SF)-36 Health Survey. To
estimate recent 3month healthcare and non-healthcare cost, and productivity loss
of FMS patients, participants completed a standardized questionnaire. Cost items
mainly included healthcare cost such as outpatient, pharmacy, inpatient, and ori-
ental medicine; non-healthcare cost such as traffic expenses, nursing cost, com-
plementary and alternative medicine. Cost included insurance-covered cost as
well as patient’s out-of-pocket expenses during 3months. To estimate productivity
loss due to morbidity, days away from work due to FMS were also investigated.
RESULTS: Among 1,040 FMS patients who completed the questionnaire, female
was 92% (n957). Approximately 45.7% of patients had rheumatic diseases. HRQoL
physical component mean scores were determined as 35.97.5, and mental com-
ponent mean scores were determined as 34.612.6. Number of out-patient visits
within 3 months was 4.06.5. Total costs over 3 months were 1,6092,055 USD.
Within 3 months, 23.4% and 91.2% of patients with FMS had been away from work
and reported the decreased work productivity, respectively. In the preceding 3
months, FMS patientsmissed 20 (SD28.1) days of work, left work early an average
of 28 (SD31.0) days, and accomplished less at work an average of 65 (SD30.0)
days. CONCLUSIONS: Our results suggested that the patient-level burden among
FMS sufferers in Korea is significant, evidenced by negative effect on health-related
quality of life, health resource use and work/activity limitations.
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RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING
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OBJECTIVES: Golimumab was recently approved by the Food and Drug Adminis-
tration onApril 24, 2009 for use in patients with rheumatoid arthritis (RA), psoriatic
arthritis (PsA), or ankylosing spondylitis (AS). The objective of this study was to
compare baseline demographic and clinical characteristics and pre-index total/RA-
related healthcare costs in patients receiving golimumab with/without biologic
experience. METHODS: The IMS LifeLink™ Health Plan database was utilized to
identify patients with an: age 18 years at index; index golimumab pharmacy
claim started 4/24/2009-10/31/2009;1 RA, PsA, or AS ICD-9 diagnosis code; and 24
months pre- and 2 months post-index continuous enrollment. RESULTS: A total
of 282 patients (n206 with pre-index biologic experience) receiving golimumab
were identified; mean SD age was 52 12; 72% female. No significant differences
in demographic characteristics existed between patients with/without biologic ex-
perience. The top three rheumatologic conditions were RA (79%), PsA (26%), and AS
(10%). Hypertension (45%), dyslipidemia (40%), and diabetes (17%) were the most
prevalent comorbidities prior to starting golimumab. Pre-index total healthcare
costs (mean, median) were significantly higher for biologic experienced patients
($59,979, $46,075) compared to non-biologic experienced patients ($21,002, $12,662;
p0.001). Among the 178 patients with an RA diagnosis only, pre-index total RA-
related costs (mean, median) were significantly higher for patients with biologic
experience ($29,701, $27,464) than those without ($6,045, $1,937; p0.001). Overall
mean  SD RA-related medication costs ($17,193  $16,619) were greater than
RA-related outpatient or inpatient costs ($5,239  $14,912 and $225  $3,001,
respectively). CONCLUSIONS:When examining baseline clinical characteristics of
patients receiving golimumab, results showed that the majority of patients were
diagnosed with RA, and had concomitant hypertension, dyslipidemia, or diabetes.
Most patients received another biologic prior to golimumab. Biologic experienced
patients were more costly at baseline. These characteristics should be adjusted for
in comparative analyses including golimumab.
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THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES: ANALYSIS FROM A
COMMERCIAL CLAIMS DATABASE
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OBJECTIVES: To determine payments made by commercial healthcare providers
for adults diagnosed with obesity, and those comorbid with any combination of
certain chronic conditions: diabetes mellitus (DM), hypertension, depression,
and/or congestive heart failure (CHF).METHODS:We utilized a 10% random sam-
pling from MarketScan, a commercial claims and encounters database
(n12,416,190). The study population (n50,717) was limited to thosewho: (1) were
adults age 18-64; (2) filed claims between 2006-2007; (3) had at least one inpatient
visit, one outpatient visit, or one emergency department visit; and, (4) were given a
primary or secondary diagnosis of obesity. Persons were identified and categorized
if they had one ormore comorbid diagnoses (DM, hypertension, depression, and/or
CHF) in addition to obesity. After adjusting for age and gender, we calculated the
mean total net expenditures (in $US 2007) for each combination of comorbid con-
ditions. All calculations were performed in Stata. RESULTS: Among those diag-
nosedwith obesity, themean net expenditures for services were $1799 per patient.
Persons diagnosed with obesity and other comorbidities observed an increase in
total net expenditures. Obesity and hypertension observed the highest increase
among single comorbidities at $4298. For persons with obesity and two other co-
morbidities, DM and depression was the highest at $14364. The most expensive
condition in the study sample was obesity, DM, hypertension and depression at
$14843. All results were statistically significant at the 95% confidence level.
CONCLUSIONS: Compared to the average medical claim, persons diagnosed with
obesity along with other common chronic conditions experience significant in-
creases in healthcare costs. These costs are often drivenhigher by the time spent as
inpatients. In many cases, obesity may be the cause of other chronic conditions
that result in these high costs. Thus, by controlling and reducing the prevalence of
obesity, we may see significant decreases in healthcare expenditures.
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OBJECTIVES: Patients managing chronic non-cancer pain with cytochrome P450
(CYP450)-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxy-
codone, tramadol) analgesics who concurrently take another CYP450-metabolized
medication experience a drug-drug exposure (DDE), which puts them at risk for a
pharmacokinetic drug-drug interaction (DDI). This study examined whether patients
with an incident DDE with the potential to cause a DDI had greater healthcare costs
compared to similar patients without such exposure. METHODS: Propensity score
matchingwas used to control for baseline differences in an insured population chron-
ically using these opioid analgesics during the period, January 1, 2004 throughDecem-
ber 31, 2008. Estimates of the predicted likelihood of a DDE occurrence for thematch-
ing model were derived from patient age, gender, geographical location, number of
unique concurrentmedications, co-morbidities, services utilization, and total costs in
the six-months pior to the index date. Comparisonsweremade between 122,586 DDE
and 122,586 no-DDE patients. RESULTS: Comparisons yielded mean total costs six
months after an incident DDE that were significantly higher for younger ( 65 years
old) patients with DDE versus matched no-DDE patients ($8,165 vs. $7,498, respec-
tively, resulting in a difference of $667, p0.01). Similarly among older ( 65years old)
patients, mean total costs at six months were significantly higher for patients with
DDE compared to matched no-DDE patients ($9,598 vs. $9,030, respectively, resulting
in a difference of $568, p0.01). The direction, magnitude and significance of these
differences persisted after sensitivity analyses. CONCLUSIONS: Although it is impos-
sible to establish causal relationships in claims database studies, this study demon-
strates a strong association of the economic consequences of DDEs that are avoidable.
Sinceconcurrentexposure tomultipledrugsmetabolized through theCYP450enzyme
system may be relatively common, policy decisions should include consideration of
the use of long-acting opioids that are not metabolized through the CYP450 pathway.
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COSTS OF CARE FOR PRIVATELY INSURED MALES WITH HEMOPHILIA IN THE
UNITED STATES, 2008
Guh S1, Grosse S1, McAlister S1, Kessler CM2, Soucie M1
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Georgetown University,
Washington, DC, USA
OBJECTIVES: Although hemophilia may have a large economic impact on patients
and healthcare systems, published estimates of costs for care of U.S. hemophilia
patients are sparse. The objective of this study is to estimate average annual costs
of health care for hemophilia patients in the United States, stratified according to
the influence of age, type of hemophilia [A (factor VIII deficiency) versus B (factor
IX)], presence of neutralizing alloantibody inhibitors, and exposure to blood-borne
viral infections.METHODS: Data from the MarketScan® Commercial and Medicare
Research Databases were used for the period 2002-2008 to identify cases of hemo-
philia and to estimatemedical expenditures during 2008. RESULTS: A total of 1,164
male hemophilia patients were identified, 933 with hemophilia A and 231 with
hemophilia B. Their average annual costs for health care in 2008 were $155,136.
Average annual costs for 30 (3%) hemophilia A patients with an inhibitor were 5
times higher than for other hemophilia patients, approximately $697,000 and
$144,000, respectively. Clotting factor concentrate accounted for 70%–82% of total
costs. Average costs for 207 adult patients with HCV or HIV infectionwere 1.5 times
higher than those for adults without infection. A subset of adults with viral infec-
tion had particularly high use of factor concentrate and costs. CONCLUSIONS:
Hemophilia treatment is associated with a significant economic burden, particu-
larly for patients with neutralizing alloantibody inhibitors who require bypassing
agents for treatment. The excess costs of care associated with blood-borne viral
infection are concentrated among a subset of hemophilia patients.
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OBJECTIVES:Obesity, defined as bodymass index (BMI) 30, is amajor contributor
to increased morbidity, mortality, and healthcare expenditures. There is a ten-
dency for obese individuals to continually gain weight over their lifetimes. How-
ever, neither the strength of this tendency nor its economic consequences are well
understood. We constructed a health outcomes model from a societal perspective
to assess this.METHODS: Our model projected lifetime trajectories for BMI, death,
cost, and quality-adjusted life years (QALYs). Using these projections, we com-
puted the net economic value of potential weight loss for an individual given base-
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